These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37345834)

  • 1. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
    Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Agarwal R; Bakris G; Chang TI; Heerspink HJL; Jardine MJ; Mahaffey KW; Neal B; Pollock C; Jun M; Rodgers A; Perkovic V; Neuen BL
    J Am Heart Assoc; 2023 Jul; 12(13):e028516. PubMed ID: 37345834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
    Sharma A; Razaghizad A; Joury A; Levin A; Bajaj HS; Mancini GBJ; Wong NC; Slee A; Ang FG; Rapattoni W; Neuen BL; Arnott C; Perkovic V; Mahaffey KW
    J Am Heart Assoc; 2024 Feb; 13(3):e031586. PubMed ID: 38240199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
    J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.
    Chen AX; Fletcher R; Neuen BL; Neal B; Arnott C
    Diabetes Obes Metab; 2024 Oct; 26 Suppl 5():5-13. PubMed ID: 39036974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
    Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
    Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
    Ye N; Jardine MJ; Oshima M; Hockham C; Heerspink HJL; Agarwal R; Bakris G; Schutte AE; Arnott C; Chang TI; Górriz JL; Cannon CP; Charytan DM; de Zeeuw D; Levin A; Mahaffey KW; Neal B; Pollock C; Wheeler DC; Luca Di Tanna G; Cheng H; Perkovic V; Neuen BL
    Circulation; 2021 May; 143(18):1735-1749. PubMed ID: 33554616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
    Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2151-2162. PubMed ID: 37161691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
    Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M;
    Am J Kidney Dis; 2023 Jul; 82(1):84-96.e1. PubMed ID: 36889425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
    Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
    Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
    Li JW; Arnott C; Heerspink HJL; MBiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ
    J Am Heart Assoc; 2022 Aug; 11(16):e025045. PubMed ID: 35929472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.